Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes

• Verfasst von: Saußele, Susanne [VerfasserIn]
• Verfasst von: Weißer, Andreas [VerfasserIn]
• Verfasst von: Müller, Martin Christian [VerfasserIn]
• Verfasst von: Emig, Michael [VerfasserIn]
• Verfasst von: La Rosée, Paul [VerfasserIn]
• Verfasst von: Paschka, Peter [VerfasserIn]
• Verfasst von: Kuhn, Christian [VerfasserIn]
• Verfasst von: Willer, Andreas [VerfasserIn]
• Verfasst von: Hehlmann, Rüdiger [VerfasserIn]
• Verfasst von: Hochhaus, Andreas [VerfasserIn]
• Titel: Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes
• Verf.angabe: S Saußele, A Weißer, MC Müller, M Emig, P La Rosée, P Paschka, C Kuhn, A Willer R. Hehlmann and A Hochhaus
• E-Jahr: 2000
• Jahr: 02 November 2000
• Umfang: 5 S.
• Fussnoten: Gesehen am 13.04.2022
• Titel Quelle: Enthalten in: Leukemia
• Ort Quelle: London : Springer Nature, 1997
• Jahr Quelle: 2000
• Band/Heft Quelle: 14(2000), 11, Seite 2006-2010
• ISSN Quelle: 1476-5551
• DOI: doi:10.1038/sj.leu.2401929
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Cancer Research
• Sach-SW: general
• Sach-SW: Hematology
• Sach-SW: Intensive / Critical Care Medicine
• Sach-SW: Internal Medicine
• Sach-SW: Medicine/Public Health
• Sach-SW: Oncology
• K10plus-PPN: 1799509052

Abstract

Recently, a polymorphic base in exon 13 of the BCR gene (exon b2 of the major breakpoint cluster region) has been identified in the eighth position before the junctional region of BCR-ABL cDNA. Cytosine replaces thymidine; the corresponding triplets are AAT (T allele) and AAC (C allele), respectively, both coding for asparagine. Therefore, this polymorphism has no implication in the primary structure of BCR and BCR-ABL proteins. However, since the alteration is located close to the fusion region it may have a significant influence on the annealing of PCR primers, probes for real time PCR, and antisense oligonucleotides. We have developed a RT-PCR-based screening method to easily identify polymorphic BCR and BCR-ABL alleles in CML patients and normal individuals in order to estimate their frequency. After amplification from cDNA, a melting curve of a specific fluorogenic probe mapping to the 3′ end of BCR exon b2 and spanning the polymorphism readily discriminates between normal and polymorphic BCR and BCR-ABL alleles. This reporter probe is 3′ labeled with fluorescein and placed next to 5′ LC Red640-labeled anchor probes mapping to the 5′ ends of BCR exon b3 or ABL exon a2 so that resonance energy transfer occurs when the probes are hybridized (LightCycler technology). T and C alleles were discriminated by a melting temperature difference of the reporter probe of 3.2 K. We have investigated cDNAs derived from leukocytes from seven cell lines and a total of 229 individuals: normal donors, n = 15; BCR-ABL negative chronic myeloproliferative disorders, n = 30; BCR-ABL negative acute leukemias, n = 11; b2a2BCR-ABL positive CML, n = 93; and b3a2BCR-ABL positive CML, n = 80. The frequency of the C allele was 33.0% in BCR-ABL negative individuals, 30.6% in b2a2BCR-ABL, and 23.8% in b3a2BCR-ABL positive CML. In CML patients, 27.7% of BCR-ABL and 27.2% of BCR alleles had the C allele (NS). In total, 132 of 458 (28.8%) exons b2 of BCR or BCR-ABL alleles demonstrated this polymorphism. We conclude that a thymidine/cytosine replacement occurs frequently in BCR exon b2. Probes for real time quantitative RT-PCR should be designed not to map to the critical region in order to avoid underestimation of the number of BCR-ABL transcripts.